Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
Self-citationEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N., & Mann, M. (2014) · Nature Methods · doi:10.1038/nmeth.2834 · Cited by 1,719 · cited 2×
“Subsequently, the low-abundance peptides were digested with specific proteases followed by desalting on C18-filled tips (stage tips) (Aebersold and Mann, 2003; Kulak et al., 2014; Rappsilber et al., 2007); they were then and analyzed using state of the art mass spectrometry (Meissner et al.”
MethodSelf-citationPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 1×
“…that secretion of GLP-1 is blunted in some subjectswith type 2 diabetes, and recent large-scale human studies suggest that the decreased GLP-1 responses may contribute to the development of type 2 diabetes (Calanna et al., 2013; Færch et al., 2015; Meier and Nauck, 2010; Nauck et al., 2011).”
BackgroundSelf-citationThe Coming Age of Complete, Accurate, and Ubiquitous Proteomes
Mann, M., Kulak, N. A., Nagaraj, N., & Cox, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.029 · Cited by 350 · cited 2×
“The concentrations of proteins and peptides in plasma range from picomolar to millimolar, a factor of 10(9), and this constitutes the main challenge for analyzing low-abundance peptides in plasma (Mann et al., 2013).”
BackgroundSelf-citationOn the Development of Plasma Protein Biomarkers
Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., & Aebersold, R. (2011) · Journal of Proteome Research · doi:10.1021/pr1008515 · Cited by 334 · cited 2×
“Importantly, and in contrast to current targeted mass spectrometry-based detection methods (Fonslow et al., 2011; Gillette and Carr, 2013b; Keshishian et al., 2007b; Parker and Borchers, 2014; Surinova et al., 2011) (e.”
MethodResultFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · cited 1×
“…that secretion of GLP-1 is blunted in some subjectswith type 2 diabetes, and recent large-scale human studies suggest that the decreased GLP-1 responses may contribute to the development of type 2 diabetes (Calanna et al., 2013; Færch et al., 2015; Meier and Nauck, 2010; Nauck et al., 2011).”
BackgroundCalanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251 · cited 2×
“First, it is well established that secretion of GLP-1 is blunted in some subjectswith type 2 diabetes, and recent large-scale human studies suggest that the decreased GLP-1 responses may contribute to the development of type 2 diabetes (Calanna et al., 2013; Færch et al., 2015; Meier and Nauck, 2010; Nauck et al., 201…”
BackgroundSelf-citationMeier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Cited by
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationTan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
Self-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
Self-citationStriking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“This process occurs in the intestinal L cells of the gastrointestinal tract leading to the co-secretion of GLP-1 and oxyntomodulin in response to nutrient sensing (19, 20).”
Background
Metadata
- Authors
- Wewer Albrechtsen, N. J., Hornburg, D., Albrechtsen, R., Svendsen, B., Toräng, S., Jepsen, S. L., Kuhre, R. E., Hansen, M., Janus, C., Floyd, A., Lund, A., Vilsbøll, T., Knop, F. K., Vestergaard, H., Deacon, C. F., Meissner, F., Mann, M., Holst, J. J., & Hartmann, B.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 7
- Pages
- 112-120
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2331051243
- Cited by
- 69
- References
- 11
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.